EpimiRNA
Bicoll © Kai Lamottke
Bicoll © Kai Lamottke

Partner 17 - Columbia University

 

 

 

 

Prof. David Goldstein

Principal Investigator
Director, Institute for Genomic Medicine

undefinedE-Mail

undefinedPubMed

undefinedResearchGate

Institute for Genomic Medicine at Columbia University

Institute for Genomic Medicine Columbia University Medical Center
701 W 168th St, 1408
New York City, NY 10032

undefinedWebsite

 

EpimiRNA Team Columbia

Dr. Brian Krueger

Director of Operations

undefinedE-Mail

  

Michelle Gutwein

Project Manager

 undefinedE-Mail

Chantal Boucher

Project Manager

undefinedE-Mail

Ayal Gussow

Graduate Student

undefinedE-Mail


Melody McSweeney

Graduate Student

undefinedE-Mail


Dr. Matthew Halvorsen

Postdoc

undefinedE-Mail

Institute presentation

The Institute for Genomic Medicine was established in January of 2015 under the direction of Dr. David Goldstein as a part of Columbia University's Precision Medicine Initiative. The overarching goal of the institute is to create a cohesive research and teaching environment for human genetics and genomics within Columbia. Recent technological advances in genome sequencing and adoption of electronic medical records enabled the creation of patient-centered personalized medicine being one of the the keystones of the medical field. The sequencing facility at IGM consists of a 3000 square foot facility that has four Illumina HiSeq2500 sequencers. Currently, the sequencing capacity for the facility is 160 whole genomes or 1500 whole exomes per month.

 

David Goldstein is the author of over 200 scholarly publications in the areas of population and medical genetics. His principal interests include human genetic diversity, the genetics of disease, and pharmacogenetics. He was elected a fellow of AAAS in 2013 and was a recipient of one of the first seven nationally awarded Royal Society / Wolfson research merit awards in the UK for his work in human population genetics. Dr. Goldstein is also one of three overall principal investigators of the NINDS Epilepsy genetics Center without Walls and directs the genome sequencing and bioinformatic core of Epi4K. Epi4K is currently the largest epilepsy genetics project in the world and is in the process of generating whole exome and whole genome sequence data on no less than 4,000 patients with epilepsy.

EpimiRNA Team

EpimiRNA Work packages

EpimiRNA Work packages
Home
Top

Newsletter Subscription

EpimiRNA on @twitter

News Section

Great success of the EpimiRNA consortium resulting in EMBO publication!

Read...

Read more

Social Media

Twitter Google Plus Facebook
Home
Top